Grid Systems solutions allow the optimisation of company IT infrastructures and research centres to produce a drastic reduction of computation time and simulation costs.

For example - docking analysis in drug design, DNA & protein sequence analysis in genetics research, comparative genome analysis and the design of chemical compounds.

With grid solutions pharmaceutical companies have seen the time and cost of drug design processes reduced. Research laboratories have optimised the use of their computational resources and been able to extend and scale their research processes.

Drug design programmes, with their chemical simulations, can greatly benefit from IG V in two processes. Design, based on a Gaussian package, is easily implemented in an IG V platform and, similarly, docking integrates extremely well.

For pharmaceutical companies, the business value of IG V lies in scalability and enhanced process speed. Computations that traditionally take weeks are reduced to days or hours and others that would simply be out of reach, become feasible with the same IT resources. And the opportunity to increase the study base makes research more effective.

The IG V platform, thereby, allows the design cycle to be shortened ... providing companies with a competitive market advantage.

At Taisho Pharmaceutical, for instance, it allowed research groups to run in-silico docking experiments, covering a broad range of compounds and proteins (peptides and drugs) in a much more efficient way. For these analyses require a great amount of computing time – which were considered unfeasible using conventional computational methods. Now, with IG V as part of the solution, the computing time is drastically reduced. So too is the time-to-market for new drugs and the first stage drug discovery costs.